Published in Clin Cancer Res on January 01, 1999
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood (2012) 2.86
A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. Mol Cancer Ther (2009) 1.54
Bladder Cancer Immunotherapy: BCG and Beyond. Adv Urol (2012) 1.27
Interleukin 12: still a promising candidate for tumor immunotherapy? Cancer Immunol Immunother (2014) 1.17
Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12. Cancer Res (2009) 1.12
Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest New Drugs (2005) 1.08
Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells. Cancer Res (2008) 1.03
Gadd45b and Gadd45g are important for anti-tumor immune responses. Eur J Immunol (2009) 1.00
Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. Scientifica (Cairo) (2014) 0.94
Coexpression of IL-18 strongly attenuates IL-12-induced systemic toxicity through a rapid induction of IL-10 without affecting its antitumor capacity. J Immunol (2009) 0.88
IL-12 enhances the generation of tumour antigen-specific Th1 CD4 T cells during ex vivo expansion. Clin Exp Immunol (2004) 0.88
Soypeptide lunasin in cytokine immunotherapy for lymphoma. Cancer Immunol Immunother (2013) 0.85
The immunocytokine NHS-IL12 as a potential cancer therapeutic. Oncotarget (2014) 0.83
Optimized expression and specific activity of IL-12 by directed molecular evolution. Proc Natl Acad Sci U S A (2003) 0.83
Vaccination with Gag, Vif, and Nef gene fragments affords partial control of viral replication after mucosal challenge with SIVmac239. J Virol (2014) 0.82
Myxoma virus expressing human interleukin-12 does not induce myxomatosis in European rabbits. J Virol (2007) 0.80
Mathematical modeling of Interleukin-35 promoting tumor growth and angiogenesis. PLoS One (2014) 0.80
Cloning and characterization of an adenoviral vector for highly efficient and doxycycline-suppressible expression of bioactive human single-chain interleukin 12 in colon cancer. BMC Biotechnol (2007) 0.79
Late administration of murine CTLA-4 blockade prolongs CD8-mediated anti-tumor effects following stimulatory cancer immunotherapy. Cancer Immunol Immunother (2015) 0.79
Interleukin-12 preserves the cutaneous physical and immunological barrier after radiation exposure. Radiat Res (2015) 0.78
Intricacies for posttranslational tumor-targeted cytokine gene therapy. Mediators Inflamm (2013) 0.78
Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis. Breast Cancer Res (2015) 0.78
Inhibition of a vascular ocular tumor growth by IL-12 gene transfer. Clin Exp Metastasis (2007) 0.76
Adenovirus-mediated interleukin-12 gene transfer combined with cytosine deaminase followed by 5-fluorocytosine treatment exerts potent antitumor activity in Renca tumor-bearing mice. BMC Cancer (2005) 0.76
Oncolytic adenovirus coexpressing interleukin-12 and shVEGF restores antitumor immune function and enhances antitumor efficacy. Oncotarget (2016) 0.75
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 10.20
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol (2001) 9.68
Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med (1988) 8.90
Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med (1985) 8.21
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med (1987) 7.33
Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med (1989) 6.66
The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ (2011) 5.95
Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med (1990) 5.27
Ia determinants on human T-cell subsets defined by monoclonal antibody. Activation stimuli required for expression. J Exp Med (1979) 5.19
A monoclonal antibody to human acute lymphoblastic leukaemia antigen. Nature (1980) 3.90
Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell (1985) 3.86
Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood (1994) 3.74
Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg (1989) 3.58
Biology and clinical relevance of human natural killer cells. Blood (1990) 3.50
NIH conference. Hepatocellular carcinoma. Ann Intern Med (1988) 2.94
Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med (1996) 2.92
HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene (2010) 2.91
HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells. Leukemia (2010) 2.83
Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J Exp Med (1990) 2.79
The welfare of the child. An emerging issue in the regulation of assisted conception. Hum Reprod (1998) 2.79
Generation of monoclonal antibodies to a human natural killer clone. Characterization of two natural killer-associated antigens, NKH1A and NKH2, expressed on subsets of large granular lymphocytes. J Clin Invest (1985) 2.77
In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol (1985) 2.73
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol (2001) 2.71
Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med (1996) 2.69
Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp Hematol (1996) 2.68
Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood (1997) 2.66
Activation of cytolytic T lymphocyte and natural killer cell function through the T11 sheep erythrocyte binding protein. Nature (1985) 2.51
Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res (1981) 2.49
Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood (2001) 2.40
Expression of myeloid differentiation antigens on normal and malignant myeloid cells. J Clin Invest (1981) 2.34
The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ (2009) 2.30
Treponema pallidum major sheath protein homologue Tpr K is a target of opsonic antibody and the protective immune response. J Exp Med (1999) 2.29
Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med (1992) 2.26
Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis. Am J Pathol (1992) 2.19
Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest (1993) 2.18
Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. Science (1994) 2.10
Ionizing radiation induces expression and binding activity of the nuclear factor kappa B. J Clin Invest (1991) 2.08
Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annu Rev Immunol (1986) 2.08
Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res (1997) 2.08
PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies. Hum Mol Genet (1999) 2.08
Increase in the 64-kDa subunit of the polyadenylation/cleavage stimulatory factor during the G0 to S phase transition. Proc Natl Acad Sci U S A (1998) 2.01
MacMolPlt: a graphical user interface for GAMESS. J Mol Graph Model (1998) 2.00
Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma. J Exp Med (1988) 1.98
Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery (1988) 1.98
Phenotypic and functional heterogeneity of human cloned natural killer cell lines. Nature (1983) 1.93
A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest (1981) 1.93
Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst (1993) 1.91
An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N Engl J Med (1990) 1.89
B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J Clin Invest (1997) 1.84
Analysis of T-cell receptor gene rearrangement and expression in human natural killer clones. Science (1985) 1.83
CD3-negative natural killer cells express zeta TCR as part of a novel molecular complex. Nature (1989) 1.82
The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors. J Immunol (1980) 1.81
Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood (1981) 1.77
IL-6/IFN-beta-2 as a circulating hormone. Induction by cytokine administration in humans. J Immunol (1989) 1.75
Human natural killer cell adhesion molecules. Differential expression after activation and participation in cytolysis. J Immunol (1990) 1.74
Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst (1988) 1.73
Establishment of a Ph1-positive human cell line (BV173). J Natl Cancer Inst (1983) 1.72
Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes. J Immunol (1993) 1.69
Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. Bone Marrow Transplant (2010) 1.68
Fc gamma receptor type III (CD16) is included in the zeta NK receptor complex expressed by human natural killer cells. Proc Natl Acad Sci U S A (1990) 1.66
Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest (1996) 1.64
Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res (1994) 1.64
A subset of natural killer cells in peripheral blood displays a mature T cell phenotype. J Exp Med (1986) 1.63
Identification of a clonally restricted 90 kD heterodimer on two human cloned natural killer cell lines. Its role in cytotoxic effector function. J Exp Med (1983) 1.62
Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer (2000) 1.62
High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol (1998) 1.61
Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4. Blood (2000) 1.60
Advice on low-fat diets for obesity. Cochrane Database Syst Rev (2002) 1.60
Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer (1986) 1.60
A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapy. J Clin Oncol (1990) 1.59
Identification and molecular cloning of the human Blym transforming gene activated in Burkitt's lymphomas. Nature (1983) 1.58
Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol (2001) 1.58
Comparative expression of T9, T10, and Ia antigens on activated human T cell subsets. Hum Immunol (1981) 1.57
Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts. Br J Cancer (2013) 1.57
Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage. Blood (1981) 1.57
Generation of a cloned NK cell line derived from the "null cell" fraction of human peripheral blood. J Immunol (1982) 1.56
Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J Clin Immunol (1988) 1.56
Nosocomial sepsis associated with interleukin-2. Ann Intern Med (1990) 1.56
Further analysis of interleukin-2 receptor subunit expression on the different human peripheral blood mononuclear cell subsets. Blood (1998) 1.56
Early versus delayed shoulder motion following axillary dissection: a randomized prospective study. Ann Surg (1981) 1.54
Selective expression of the common acute lymphoblastic leukemia (gp 100) antigen on immature lymphoid cells and their malignant counterparts. Blood (1983) 1.54
Should we recommend low-fat diets for obesity? Obes Rev (2003) 1.53
Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood (1998) 1.52
A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer (2000) 1.52
Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res (2001) 1.51
Randomized investigation of magnesium sulfate for prevention of preterm birth. Am J Obstet Gynecol (1990) 1.51
In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J Immunol (1985) 1.50
Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. J Immunol (1987) 1.50
A prospective randomized trial evaluating colloid versus crystalloid resuscitation in the treatment of the vascular leak syndrome associated with interleukin-2 therapy. J Immunother Emphasis Tumor Immunol (1994) 1.49
Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells. J Clin Oncol (1990) 1.49
Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat Med (1999) 1.47
Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol (1988) 1.46